Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + abiraterone nanocrystal for locally advanced prostate cancer
ChiCTR2500105230Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and abiraterone in prostate cancer (PCa), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Minimal residual disease (minimum residual lesions). Started Jul 2025; status: recruiting.
02
Drugs
docetaxelabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500105230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105230.